Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C4H9NO3 |
Molecular Weight | 119.1192 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](O)[C@H](N)C(O)=O
InChI
InChIKey=AYFVYJQAPQTCCC-GBXIJSLDSA-N
InChI=1S/C4H9NO3/c1-2(6)3(5)4(7)8/h2-3,6H,5H2,1H3,(H,7,8)/t2-,3+/m1/s1
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8296531 | https://www.ncbi.nlm.nih.gov/pubmed/1905383 | https://www.ncbi.nlm.nih.gov/pubmed/12523390
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8296531 | https://www.ncbi.nlm.nih.gov/pubmed/1905383 | https://www.ncbi.nlm.nih.gov/pubmed/12523390
L-threonine is an essential amino acid. Threonine is a precursor of glycine. The biochemical studies on rats proved that glycine is synthesized from threonine (through threonine dehydrogenase pathway). Threonine dehydrogenase is the key enzyme in mammals like pigs, cat, and rats for degradation of 80% threonine. In adult humans, degradation of 7–11% of threonine is done by threonine dehydrogenase. The human L-threonine 3-dehydrogenase gene (GeneID: 157739, UniProtKB: Q8IZJ6 (TDH_HUMAN)) is an expressed pseudogene having lost the splice acceptor site preceding exon 6 and codon arginine-214 (CGA) is mutated to a stop codon (TGA). A few trials demonstrated that oral L-threonine may alleviate clinical signs of amyotrophic lateral sclerosis and spasticity in humans. L-Threonine has recently been brought into agricultural industry for balancing the livestock feed.
Originator
Sources: http://www.jbc.org/content/112/1/283.full.pdf
Curator's Comment: reference retrieved from http://www.jbc.org/content/115/3/721.full.pdf
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: EC 1.1.1.103 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10780944/ |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FREAMINE III 10% Approved UseParenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is
indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric
patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or
should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal
absorption of protein is impaired; or (3) protein requirements are substantially increased as with
extensive burns. Dosage, route of administration, and concomitant infusion of non-protein
calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date1971 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
200 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/685879/ |
15 mg/kg single, intravenous dose: 15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
THREONINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
300 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/685879/ |
15 mg/kg single, intravenous dose: 15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
THREONINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/685879/ |
15 mg/kg single, intravenous dose: 15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
THREONINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. | 2001 |
|
The first constant-domain (CH1) exon of human IGHG2 is polymorphic and in strong linkage disequilibrium with the CH2 exon polymorphism encoding the G2m(n+) allotype in Caucasians. | 2001 |
|
Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. | 2001 |
|
A single amino-acid in the TM1 domain is an important determinant of the desensitization kinetics of recombinant human and guinea pig alpha-homomeric 5-hydroxytryptamine type 3 receptors. | 2001 Apr |
|
Direct and differential interaction of beta-arrestins with the intracellular domains of different opioid receptors. | 2001 Apr |
|
Phosphoserine/threonine-binding domains. | 2001 Apr |
|
Starvation-induced lysosomal degradation of aldolase B requires glutamine 111 in a signal sequence for chaperone-mediated transport. | 2001 Apr |
|
F X Nottingham and F X Taunton. Two novel mutations in factor X resulting in loss of functional activity and an interpretation using molecular modelling. | 2001 Feb |
|
Mutation at codon 130 in hepatitis B virus (HBV) core region increases markedly during acute exacerbation of hepatitis in chronic HBV carriers. | 2001 Feb |
|
Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. | 2001 Feb |
|
Molecular interactions between the specialist herbivore Manduca sexta (Lepidoptera, Sphingidae) and its natural host Nicotiana attenuata. II. Accumulation of plant mRNAs in response to insect-derived cues. | 2001 Feb |
|
Kinase suppressor of ras is necessary for tumor necrosis factor alpha activation of extracellular signal-regulated kinase/mitogen-activated protein kinase in intestinal epithelial cells. | 2001 Feb 1 |
|
Electrophysiologic endpoint measures in a multicenter ALS drug trial. | 2001 Feb 15 |
|
The ATP-dependent CodWX (HslVU) protease in Bacillus subtilis is an N-terminal serine protease. | 2001 Feb 15 |
|
LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505. | 2001 Feb 15 |
|
Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87mg cells. | 2001 Feb 2 |
|
Role of Thr(11) in the binding of omega-conotoxin MVIIC to N-type Ca2+ channels. | 2001 Feb 23 |
|
Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. | 2001 Feb 27 |
|
Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting. | 2001 Feb 8 |
|
Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. | 2001 Feb 9 |
|
Thr226 is a key residue for bioluminescence spectra determination in beetle luciferases. | 2001 Feb 9 |
|
Reduced hydrolysis of amelogenin may result in X-linked amelogenesis imperfecta. | 2001 Jan |
|
Rapid deposition of wheat cell wall structural proteins in response to Fusarium-derived elicitors. | 2001 Jan |
|
Near-infrared reflectance spectroscopy enables the fast and accurate prediction of the essential amino acid contents in soy, rapeseed meal, sunflower meal, peas, fishmeal, meat meal products, and poultry meal. | 2001 Jan |
|
Identification of tyrosine-phosphorylated proteins associated with the nuclear envelope. | 2001 Jan |
|
An HphI polymorphism in the E-selectin gene is associated with premature coronary artery disease. | 2001 Jan |
|
FMN is covalently attached to a threonine residue in the NqrB and NqrC subunits of Na(+)-translocating NADH-quinone reductase from Vibrio alginolyticus. | 2001 Jan 12 |
|
Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. | 2001 Jan 15 |
|
Serotonin activates S6 kinase in a rapamycin-sensitive manner in Aplysia synaptosomes. | 2001 Jan 15 |
|
Follicle-stimulating-hormone receptor and twinning. | 2001 Jan 20 |
|
A molecular marker for chloroquine-resistant falciparum malaria. | 2001 Jan 25 |
|
Protein control of the redox potential of the primary quinone acceptor in reactioncCenters from Rhodobacter sphaeroides. | 2001 Jan 30 |
|
Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. | 2001 Jan 4 |
|
Electrical activity regulates AChR gene expression via JNK, PKCzeta and Sp1 in skeletal chick muscle. | 2001 Jan 5 |
|
Phase-feeding supports maximum growth performance of broiler chicks from forty-three to seventy-one days of age. | 2001 Mar |
|
Studies on feeding peanut meal as a protein source for broiler chickens. | 2001 Mar |
|
A novel mechanism controls anaerobic and catabolite regulation of the Escherichia coli tdc operon. | 2001 Mar |
|
Biochemical characterization of cholesterol-3-sulfate as the sole effector for the phosphorylation of HMG1 by casein kinase I in vitro. | 2001 Mar |
|
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. | 2001 Mar |
|
Isolation and characterisation of genomic and cDNA clones coding for a serine-, alanine-, and proline-rich protein of Trypanosoma cruzi. | 2001 Mar |
|
Three-dimensional structure of human follicle-stimulating hormone. | 2001 Mar |
|
Topology and structure of the C1q-binding site on C-reactive protein. | 2001 Mar 15 |
|
Hydrophobic analogues of the winter flounder 'antifreeze' protein. | 2001 Mar 2 |
|
Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: implications for membrane fusion. | 2001 Mar 6 |
|
Expression and mutagenesis of the NqrC subunit of the NQR respiratory Na(+) pump from Vibrio cholerae with covalently attached FMN. | 2001 Mar 9 |
|
The F-box protein SKP2 binds to the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E. | 2001 Mar 9 |
|
Phosphorylation-dependent conformation and proteolytic stability of c-Myb. | 2001 Mar-Apr |
|
Sodium-substrate cotransport in bacteria. | 2001 May 1 |
|
Recent progress in the Na(+)-translocating NADH-quinone reductase from the marine Vibrio alginolyticus. | 2001 May 1 |
|
Synthesis of bisaminoacylated pdCpAs and tandemly activated transfer RNAs. | 2007 Jul 1 |
Sample Use Guides
L-threonine (4 g daily) with pyridoxal phosphate (160 mg daily) for six months in patients with amyotrophic lateral sclerosis.
Threonine supplementation (500 mg/day) was given to 6 patients with genetic spasticity syndromes for a period of 12 months, followed by a 4-month observation period without medication.
Oral L-threonine at 6 g/day in patients with spinal spasticity.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24103518
20 mM L-Threonine increases heat shock protein (HSP)70 and HSP25 expression and protects intestinal epithelial cells from heat stress injury
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
3010-6
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
47788-5
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
27179-1
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
32272-7
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
47789-3
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
3009-8
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
44413-3
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
20658-1
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
30057-4
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
47785-1
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
3008-0
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
3007-2
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
JECFA EVALUATION |
L-THREONINE
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
62191
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
25988-7
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
13416-3
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
27322-7
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
22688-6
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
13815-6
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
26897-9
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
33888
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
15144-9
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
25540-6
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
DSLD |
167 (Number of products:18)
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
32273-5
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
3006-4
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
22740-5
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
25989-5
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
47784-4
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
22643-1
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
DSLD |
2066 (Number of products:732)
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
17704-8
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
47790-1
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
47786-9
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
47787-7
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
15134-0
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
||
|
LOINC |
56641-4
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2096
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
46701
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
DTXSID2046412
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
DB00156
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
57926
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
1667202
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
26986
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
10524
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | RxNorm | ||
|
6172
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
THREONINE
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
m10804
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
200-774-1
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
2ZD004190S
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
30013
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
6288
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
4254
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
D013912
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
SUB10989MIG
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
2ZD004190S
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
100000092365
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
16857
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
C29602
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
SUB21991
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
72-19-5
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL291747
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
16589
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY | |||
|
7797
Created by
admin on Sat Dec 16 17:51:52 GMT 2023 , Edited by admin on Sat Dec 16 17:51:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY